Caplyta Cost in 2026: Prices & How to Save
The pharmacy rings up $1,761.69 for thirty capsules. Same price at 10.5 mg, 21 mg, or 42 mg. If you're taking it long term, the Caplyta cost works out to a little over $21,000 a year for one prescription.
Most articles about this drug send you straight to a coupon page. Fine as far as it goes. But it skips the two things that actually determine what you'll pay over the next several years: how Caplyta is priced per capsule, and how long it will stay brand-only.
At a glance
- US cash price for Caplyta runs about $1,761.69 for 30 capsules, or roughly $58.72 per capsule (Drugs.com, August 2026).
- Every strength costs the same — 10.5 mg, 21 mg, and 42 mg are all priced identically, so a lower dose won't lower your bill.
- No generic lumateperone exists in the US. A settlement with Sandoz sets generic entry no earlier than July 1, 2040.
- Caplyta picked up a fourth FDA indication in November 2025 (add-on treatment for major depressive disorder), which is pushing more people toward a drug with no cheaper equivalent.
- Several atypical antipsychotics in the same class are available generically for under $60 a month through cash-pay routes — worth raising with your prescriber if cost is the barrier.
How much does Caplyta cost without insurance?
Roughly $1,762 for a 30-day supply. Published cash prices in 2026 land between about $1,470 and $2,306 depending on which pharmacy and which pricing source you check, which is a spread of more than $800 for the identical product.
| Strength | Quantity | US cash price | Per capsule |
|---|---|---|---|
| 10.5 mg | 30 capsules | $1,761.69 | $58.72 |
| 21 mg | 30 capsules | $1,761.69 | $58.72 |
| 42 mg | 30 capsules | $1,761.69 | $58.72 |
US cash pricing per Drugs.com, August 2026. Retail prices vary by pharmacy, region, and pricing source.
Look at that table for a second, because it changes what advice is useful.
Caplyta is priced flat per capsule. The 42 mg capsule — the standard dose for schizophrenia and bipolar depression — costs exactly what the 10.5 mg capsule costs. So the most commonly repeated cost tip in psychiatry, ask your doctor whether a lower dose would work, saves you nothing here. It might be the right clinical call for other reasons. It won't move your pharmacy bill.
Splitting isn't an option either. Caplyta is a capsule, and the prescribing information doesn't support opening or dividing it.
What does move your cost is quantity and source. A 90-day fill and a cash-pay route are the two levers that exist.
Annualized, the picture is stark: about $21,140 per year at retail, before a single doctor's visit or lab draw.
Why is Caplyta so expensive?
No competition, and none coming for a long while.
Lumateperone is protected by a dense patent estate — more than two dozen patents covering the compound, its salt forms, and its formulation. Nobody else can legally sell it in the US, so there's no generic pressure on price and no reason for the manufacturer to discount.
The ownership picture reinforces it. Caplyta came from Intra-Cellular Therapies, which Johnson & Johnson acquired in 2025 in a deal valued at roughly $14.6 billion. A drug bought at that price is not one the buyer discounts voluntarily.
There's also a structural reason unique to US pricing. Drug prices here are negotiated plan by plan rather than set nationally, and rebates flow to insurers and pharmacy benefit managers rather than to individuals. Cash-paying patients sit at the top of that ladder, not the bottom — you're quoted the list price precisely because you have nobody negotiating on your behalf.
Is there a generic for Caplyta? And when is it coming?
There is no generic lumateperone available in the United States, and this is where most cost articles stop.
The more useful answer is the date. In January 2025, Intra-Cellular Therapies settled patent litigation with Sandoz, which had filed an abbreviated new drug application seeking approval for a generic version. Under the terms of that settlement, Sandoz may begin selling generic lumateperone on July 1, 2040 — or earlier under certain circumstances the companies didn't disclose.
Fourteen years.
Two other generic manufacturers hold tentative FDA approvals for lumateperone tosylate, which means their applications have cleared review on the merits and are waiting only on patent clearance. That's worth knowing because it signals real generic interest, and settlements of this type sometimes contain earlier trigger dates tied to other litigation outcomes. But nothing about that is public, and nothing about it is something you can plan a medication budget around.
Savings tip: If you've been waiting out the brand-only period on the assumption a generic is a year or two away, that assumption is worth revisiting. Planning around 2040 pricing and planning around today's pricing produce very different decisions about a 90-day fill, a cash-pay route, or a conversation with your prescriber about alternatives.
Be careful with sites offering "generic Caplyta" or generic lumateperone online. Lumateperone generics may exist in countries where the patents were never filed, but no version has been reviewed by the FDA and there's no legitimate US supply. A real pharmacy requires a valid prescription, holds a verifiable license, and puts you in touch with a pharmacist. An operation selling an unapproved generic without a prescription meets none of those tests.
What Caplyta treats — and why 2025 changed the cost conversation
Caplyta is an atypical antipsychotic. It's FDA-approved for four uses in adults:
- Schizophrenia (approved December 2019)
- Depressive episodes of bipolar I or bipolar II disorder, alone or alongside lithium or valproate (2021)
- Bipolar I and II depression as monotherapy and adjunctive therapy
- Major depressive disorder as an add-on to an antidepressant — approved November 6, 2025
That last one matters for cost. The MDD indication opens Caplyta to a far larger patient population than schizophrenia or bipolar depression, and it arrived based on two Phase III trials that showed improvements of 4.9 and 4.5 points on the MADRS depression scale versus placebo, without the mean weight gain or metabolic shifts that make several older antipsychotics hard to tolerate.
That tolerability profile is a genuine clinical advantage, and it's a large part of why prescribers reach for Caplyta. It's also why the cost question is landing on so many more kitchen tables than it was two years ago.
One small point that comes up constantly: Caplyta is not a controlled substance. It carries no DEA schedule, which means no special refill restrictions on the pharmacy side.
Does insurance cover Caplyta?
Usually, but with conditions that often leave you paying full price anyway.
The manufacturer reports coverage for roughly 90% of people with commercial insurance and more than 99% of eligible Medicaid and Medicare Part D patients. Coverage on paper and coverage in practice aren't the same thing.
Caplyta typically sits on a high formulary tier, and plans commonly attach prior authorization, step therapy, or both. Step therapy means you have to try and fail on one or more cheaper antipsychotics before your plan will pay. If your prescriber has already documented failures on other agents, that history is what gets the approval — incomplete documentation is one of the most common reasons for denial, and appeals cost weeks you may not have if you're mid-titration.
And if you're on a high-deductible plan, none of it helps until you've met the deductible. In January, an insured patient and an uninsured patient often pay the identical $1,762.
Cheaper alternatives in the same class
Caplyta works differently from older antipsychotics — it has an unusual receptor profile involving serotonin 5-HT2A, dopamine D2, and the serotonin transporter, and it tends to produce less weight gain and less sedation than several alternatives. Those differences are real, and they're why people end up on it.
But if cost is the reason you're considering stopping, these are the options worth putting in front of your prescriber. Most of them have been generic for years, and even the two that haven't cost a fraction of what Caplyta does.
| Medication | US generic available | Cash-pay price |
|---|---|---|
| Caplyta (lumateperone) | No — not before 2040 | $1,761.69 / 30 caps (US retail) |
| Vraylar (cariprazine) | No | $200.99 / 30 caps |
| Rexulti (brexpiprazole) | No | $142.99 / 30 tabs |
| Abilify / aripiprazole | Yes | $110.99 / 100 tabs |
| Seroquel / quetiapine | Yes | $27.99–$35.99 / 60 tabs |
| Zyprexa / olanzapine | Yes | $56.99–$65.99 |
| Latuda (lurasidone) | Yes | Varies by strength |
CanAmerica Plus cash-pay pricing as of August 2026, except where noted as US retail.
A few things worth knowing before you raise any of these:
Quetiapine is the only other medication FDA-approved for both bipolar I and bipolar II depression, which makes it the most common starting point when Caplyta isn't affordable. It's also sedating and carries meaningful weight and metabolic risk — a real tradeoff, not a free swap.
Lurasidone (sold as Latuda) carries the bipolar depression indication with a lower weight-gain profile than quetiapine, which makes it the closer match on tolerability. The catch is absorption: it has to be taken with a meal of at least 350 calories, and for some people that's a genuine adherence problem.
Aripiprazole is cheap, widely used, and generally activating rather than sedating. At about $1.11 per tablet it runs roughly $33 a month.
Olanzapine works, but it's among the worst offenders in this class for weight gain and metabolic effects.
One odd detail worth checking on any of these: brand and generic aren't always priced the way you'd expect. Brand-name Seroquel runs $27.99 for 60 tablets through CanAmerica Plus while generic quetiapine runs $35.99 for the same count. Sourcing and packaging differences occasionally make the brand the cheaper line item. Look at both before assuming.
None of this is a recommendation to switch. If you've cycled through three antipsychotics to find one that works and Caplyta is the one, that's a strong clinical reason to stay put. Bring the number to your prescriber and let them weigh it against your history. Never stop or swap an antipsychotic on your own — abrupt discontinuation can trigger withdrawal effects or relapse.
How to lower what you pay for Caplyta now
Fill 90 days at a time. Nothing about flat per-capsule pricing rewards monthly fills, and fewer refills means fewer trips, fewer shipping charges, and fewer chances to run out.
Compare cash-pay pricing against your actual copay, not against retail. People assume insurance always wins. On a high-deductible plan early in the plan year, it frequently doesn't. Run that comparison in December, before the deductible resets, not in June.
Get the prior authorization documented properly the first time. If your plan requires step therapy and you've already failed other antipsychotics, that treatment history is the thing that gets Caplyta approved. Ask your prescriber's office to include it up front.
Shop the price, not just the pharmacy. The $800-plus spread between published cash prices for the same 30 capsules is not a rounding error. Call three pharmacies before you fill.
Tell your prescriber if cost is why you're skipping doses. Stretching capsules to make a prescription last is a clinical problem, not just a financial one, and it changes what a psychiatrist would recommend. They can't account for a barrier they don't know about.
The bottom line
Caplyta costs about $1,762 a month at US retail, the price doesn't drop at lower doses, and no generic is coming before 2040 under the current settlement. That combination means the savings decisions available to you are structural rather than temporary — a longer fill, a different source, or a conversation with your prescriber about whether a generic in the same class fits your history.
If you're paying full retail right now, compare that number against cash-pay pricing before your next refill. And if the cost is the reason you've been considering stopping, say so out loud at your next appointment before you do.
Frequently asked questions
How much does a 30-day supply of Caplyta cost?
About $1,761.69 for 30 capsules at US cash pricing as of August 2026, which works out to roughly $58.72 per capsule. Published prices from other sources range from about $1,470 to $2,306 for the same quantity, so it's worth calling more than one pharmacy.
Is there a generic version of Caplyta?
No. Lumateperone is brand-only in the United States. A 2025 patent settlement with Sandoz permits generic entry no earlier than July 1, 2040, though the agreement allows for earlier entry under undisclosed circumstances.
Does a lower dose of Caplyta cost less?
No. All three strengths — 10.5 mg, 21 mg, and 42 mg — are priced identically per capsule. Reducing your dose won't reduce your pharmacy bill. Only the number of capsules affects the total, and that isn't something to change on your own.
Will insurance cover Caplyta?
Most commercial and Medicare Part D plans list it, but usually on a high tier with prior authorization or step therapy attached. You may need to document failure on a cheaper antipsychotic first, and on a high-deductible plan you'll pay the full price until the deductible is met.
Is Caplyta a controlled substance?
No. Caplyta has no DEA schedule and isn't classified as a controlled substance, so standard refill rules apply.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment. Pricing information is current as of the publication date but may change. Verify pricing directly before making purchasing decisions.
